Flaminal
Commercial- Indications
- Acute wounds, Chronic wounds
Company intelligence / Profile preview
Flen Health has a strong commercial presence with established products like Flamigel® and Flaminal®, which are widely used in over 30 countries. Their latest innovation, VES 0—an enhancement of the Flaminal® technology—has shown promising preclinical results and will enter Phase 0 clinical trials soon. The company’s enzyme/protein platforms are recognized for their effectiveness in difficult-to-heal wounds and have received significant external R&D funding.
4 more assets in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Flen Health.